Peer-Reviewed Publications

PipelineCategoryTitleLink
FF-10101ConferenceASH 2015: Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations

https://ash.confex.com/ash/2015/webprogramscheduler/Paper79249.html

FF-10832ArticleFF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model. Cancer Sci. 2019 Sep;110(9):2933-2940.

https://pubmed.ncbi.nlm.nih.gov/31278877/

FF-10832ConferenceAACR 2017: Liposomal gemcitabine, FF-10832, improves gemcitabine (GEM) pharmacokinetics (PK) and increases anti-tumor efficacy

https://cancerres.aacrjournals.org/content/77/13_Supplement/5148

FF-10832ConferenceAACR 2019: FF-10832 combined with immune checkpoint blockade shows favorable anti-tumor activity

https://cancerres.aacrjournals.org/content/79/13_Supplement/3953

FF-10832ConferenceAACR 2019: A phase I dose-escalation and immune biomarker study of intravenous FF-10832, liposomal gemcitabine, in patients with advanced solid tumors

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.TPS3163

FF-10850ConferenceAACR2019: FF-10850, a novel liposomal topotecan, achieved superior anti-tumor effects and a favorable safety profile via preferential distribution followed by dual payload release mechanisms in tumors

https://cancerres.aacrjournals.org/content/79/13_Supplement/1228

FF-10850ConferenceAAPS PharmaSci360 2019: Development of Pharmacokinetic-Pharmacodynamic Models for Tumor Growth Inhibition and Neutropenia after Administration of Liposomal Topotecan Injection, FF-10850

https://www.eventscribe.com/2019/PharmSci360/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=240506&rnd=0.256331&mode=posterinfo

FF-10502ArticleFF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135.

https://pubmed.ncbi.nlm.nih.gov/29653962/

FF-10502ConferenceAACR 2017: First-in-human phase 1 trial of pyrimidine anti-metabolite FF-10502-01 in patients with advanced cancer

https://cancerres.aacrjournals.org/content/77/13_Supplement/CT100

FF-10502ConferenceAACR 2018: A novel antimetabolite, FF-10502-01 exhibits potent antitumor activity via inhibition of both DNA replication and DNA damage repair in solid tumor cells

https://cancerres.aacrjournals.org/content/78/13_Supplement/326

FF-10502ConferenceASCO 2019: Phase 1/2 trial of FF-10502-01, a pyrimidine antimetabolite, in patients with advanced cholangiocarcinoma and solid tumors.

https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.3008

FF-21101ConferenceAACR 2017: Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic targeting P-cadherin, in advanced solid tumors

https://cancerres.aacrjournals.org/content/77/13_Supplement/CT097

FF-21101ConferenceAACR 2018: Phase 1 study of FF-21101(90Y), a radioimmunotherapeutic (RIT) targeting P-cadherin, in advanced solid tumors

https://cancerres.aacrjournals.org/content/78/13_Supplement/CT128

T-705ArticleIn vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46(4):977-81.

https://pubmed.ncbi.nlm.nih.gov/11897578/

T-705ArticleIn vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother. 2003;14(5):235-41.

https://pubmed.ncbi.nlm.nih.gov/14694986/

T-705ArticleMechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981-6.

https://pubmed.ncbi.nlm.nih.gov/15728892/

T-705ArticleEfficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007;51(3):845-51.

https://pubmed.ncbi.nlm.nih.gov/17194832/

T-705ArticleIn vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007;51(9):3168-76.

https://pubmed.ncbi.nlm.nih.gov/17606691/

T-705ArticleTreatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One. 2008;3(11):e3725.

https://pubmed.ncbi.nlm.nih.gov/19008960/

T-705ArticleEfficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 2008;80(3):377-9.

https://pubmed.ncbi.nlm.nih.gov/18762216/

T-705ArticleActivity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009;53(1):202-9.

https://pubmed.ncbi.nlm.nih.gov/18955536/

T-705ArticleT-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009;82(3):95-102.

https://pubmed.ncbi.nlm.nih.gov/19428599/

T-705ArticleEffect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res. 2009;82(3):169-71.

https://pubmed.ncbi.nlm.nih.gov/19428608/

T-705ArticleIn vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460 (7258):1021-5.

https://pubmed.ncbi.nlm.nih.gov/19672242/

T-705ArticleIntracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother. 2009;64(4):741-6.

https://pubmed.ncbi.nlm.nih.gov/19643775/

T-705ArticleEffects of the combination of favipiravir (T-705) and oseltamivir on influenza a virus infections in mice. Antimicrob Agents Chemother. 2010;54(1):126-33.

https://pubmed.ncbi.nlm.nih.gov/19901093/

T-705ArticleT-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 2010;107(2):882-7.

https://pubmed.ncbi.nlm.nih.gov/20080770/

T-705ArticleEfficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res. 2010;86(2):121-7.

https://pubmed.ncbi.nlm.nih.gov/19874853/

T-705ArticleIn Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses. Antimicrob Agents Chemother. 2010;54(6):2517-24.

https://pubmed.ncbi.nlm.nih.gov/20350949/

T-705ArticleT-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell Culture. Antimicrob Agents Chemother. 2011;55(2):782–7.

https://pubmed.ncbi.nlm.nih.gov/21115797/

T-705ArticleMaporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antivir Chem Chemother. 2011;21(5):193-200.

https://pubmed.ncbi.nlm.nih.gov/21566265/

T-705ArticleEffective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS Negl Trop Dis. 2011;5(10):e1342.

https://pubmed.ncbi.nlm.nih.gov/22022624/

T-705ArticleCombinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice. Antiviral Res. 2012;94(1):103-10.

https://pubmed.ncbi.nlm.nih.gov/22429564/

T-705ArticleAntiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013;57(10):4673-80.

https://pubmed.ncbi.nlm.nih.gov/23856782/

T-705ArticleMechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother. 2013;57(11):5202-8.

https://pubmed.ncbi.nlm.nih.gov/23917318/

T-705ArticleSynergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virology 2013;8(11):1085-1094.

https://pubmed.ncbi.nlm.nih.gov/24563658/

T-705ArticleFavipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Research 2013;100(2) 446–454.

https://pubmed.ncbi.nlm.nih.gov/24084488/

T-705ArticleFavipiravir (T-705) Inhibits Junín Virus Infection and Reduces Mortality in a Guinea Pig Model of Argentine Hemorrhagic Fever. PLOS Neglected Tropical Diseases 2013;7(12) e2614.

https://pubmed.ncbi.nlm.nih.gov/24386500/

T-705ArticleFavipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res. 2014 Apr;104:84-92.

https://pubmed.ncbi.nlm.nih.gov/24486952/

T-705ArticleIn vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus. Arch Virol. 2014 Jun;159(6):1279-91.

https://pubmed.ncbi.nlm.nih.gov/24311151/

T-705ArticleThe broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep. 2015 Oct 12;5:14775

https://pubmed.ncbi.nlm.nih.gov/26456301/

T-705ArticleAntiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravi. Antiviral Res. 2016 Vol. 132 P170-177

https://pubmed.ncbi.nlm.nih.gov/27321665/

T-705ArticleModeling Severe Fever with Thrombocytopenia Syndrome Virus Infection in Golden Syrian Hamsters: Importance of STAT2 in Preventing Disease and Effective Treatment with Favipiravir. J Virol. 2017 Jan 18;91(3):e01942-16.

https://pubmed.ncbi.nlm.nih.gov/27881648/

T-705ArticleT-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug. Acta Virol.

https://pubmed.ncbi.nlm.nih.gov/28105854/

T-705ArticleFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 93, 449-463.

https://pubmed.ncbi.nlm.nih.gov/28769016/

T-705ArticleEffective Treatment of Experimental Lymphocytic Choriomeningitis Virus Infection: Consideration of Favipiravir for Use With Infected Organ Transplant Recipients. J Infect Dis. 2018 Jul 13;218(4):522-527.

https://pubmed.ncbi.nlm.nih.gov/29762684/

T-705ArticleFavipiravir (T-705) protects against Nipah virus infection in the hamster model. Sci Rep. 2018 May 15;8(1):7604.

https://pubmed.ncbi.nlm.nih.gov/29765101/

T-705ArticleUse of Favipiravir to Treat Lassa Virus Infection in Macaques. Emerg Infect Dis. 2018 Sep;24(9):1696-1699.

https://pubmed.ncbi.nlm.nih.gov/29882740/

T-705ArticleFavipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. Antiviral Res. 2018 Sep;157:18-26.

https://pubmed.ncbi.nlm.nih.gov/29936152/

T-705ArticleTherapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in a lethal mouse model: Dose-efficacy studies upon oral administration. PLoS One. 2018 Oct 26;13(10):e0206416.

https://pubmed.ncbi.nlm.nih.gov/30365543/

T-705ArticleReevaluation of the efficacy of favipiravir against rabies virus using in vivo imaging analysis.Antiviral Res. 2019 Dec; 172:104641.

https://pubmed.ncbi.nlm.nih.gov/31672666/

T-705ArticleVascular Leak and Hypercytokinemia Associated with Severe Fever with Thrombocytopenia Syndrome Virus Infection in Mice. Pathogens. 2019 Sep 21;8(4). pii: E158.

https://pubmed.ncbi.nlm.nih.gov/31546590/